secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262508
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M
------------------------------------------------------------------------

- Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).
- Net loss $8.7M, a 15% improvement YoY; Adjusted EBITDA loss $4.6M, improvement of 18%.
- Lung diagnostic testing revenue $19.8M (+16% YoY); Development Services $1.9M (+97% YoY).
- Raised FY2025 total revenue guidance to $84-86M from prior range.
- Cash $16.6M at Sept 30; accounts receivable increase $5.2M due to timing of collections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000119312525262508/0001193125-25-262508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000119312525262508/bdsx-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer